基于智能手机的自管理干预对双相障碍复发、症状负担与生活质量的影响:一项随机临床试验
这项评估者盲法随机临床试验纳入205例双相I型障碍患者,比较常规照护与常规照护联合智能手机自管理干预(LiveWell)。
要点
- 智能手机自管理干预未显著降低总体复发风险,但低风险个体复发风险显著降低。
- 干预降低了抑郁症状严重度并改善了关系生活质量,但未减少症状持续时间百分比。
- 低风险个体躁狂症状严重度降低,高风险个体未见获益。
核心结论
- 智能手机自管理干预未显著改善至复发时间这一主要结局,但低风险(无症状恢复)个体复发风险显著降低。
- 干预降低了抑郁症状严重度并改善了关系生活质量。
- 研究结果提示需进一步优化智能手机干预并验证其对无症状恢复个体的复发风险降低作用。
研究设计与样本
- 评估者盲法随机临床试验,2017年3月20日至2019年4月25日入组,随访48周至2020年4月10日。
- 共205例双相I型障碍患者,从芝加哥和明尼阿波利斯-圣保罗地区诊所招募,按初始临床状态分层随机分为常规照护组(81例)和常规照护联合智能手机干预组(124例)。
关键数值与推荐
- 主要结局为至复发时间;次要结局包括症状持续时间百分比、症状严重度和生活质量。
- 干预包括应用程序、教练和网站,为期16周:教练访视后6次电话呼叫,每日和每周应用签到,应用提供自适应反馈和个性化健康计划信息。
临床怎么用
- 对于处于无症状恢复期的双相I型障碍患者,可考虑使用智能手机自管理干预以降低复发风险并改善抑郁症状及关系生活质量。
- 对于高风险(持续症状、前驱期、恢复期、症状性恢复)患者,该干预未显示显著获益,需谨慎评估适用性。
局限性
- 研究未检测到总体复发风险显著降低,主要结局未达统计学显著性。
- 样本量有限,且仅纳入双相I型障碍患者,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Bipolar disorder-specific psychotherapy combined with pharmacotherapy improves relapse risk, symptom burden, and quality of life, but psychotherapy is not easily accessible. OBJECTIVE: To determine if a smartphone-based self-management intervention (LiveWell) can assist individuals with bipolar disorder to maintain wellness. DESIGN, SETTING, AND PARTICIPANTS: An assessor-blind randomized clinical trial enrolled participants from March 20, 2017, to April 25, 2019, with 48-week follow-up ending on April 10, 2020. Participants were randomly assigned to usual care or usual care plus the smartphone intervention stratified by relapse risk based on initial clinical status (low risk: asymptomatic recovery; high risk: continued symptomatic, prodromal, recovering, symptomatic recovery). Participants with bipolar disorder I were recruited from clinics in the Chicago and Minneapolis-Saint Paul areas. Data were analyzed from June 19, 2020, to May 25, 2022. INTERVENTIONS: The smartphone-based self-management intervention consisted of an application (app), coach, and website. Over 16 weeks, participants had a coach visit followed by 6 phone calls, and they completed daily and weekly app check-ins. The app provided adaptive feedback and information for developing a personalized wellness plan, the coach provided support, and the website provided summary data and alerts. MAIN OUTCOMES AND MEASURES: The primary outcome was time to relapse. Secondary outcomes were percentage-time symptomatic, symptom severity, and quality of life. RESULTS: Of the 205 randomized participants (mean [SD] age, 42 [12] years; 125 female individuals [61%]; 5 Asian [2%], 21 Black [10%], 13 Hispanic or Latino [6%], 7 multiracial [3%], 170 White [83%], 2 unknown race [1%]), 81 (40%) were randomly assigned to usual care, and 124 (60%) were randomly assigned to usual care plus the smartphone intervention. This clinical trial did not detect a reduction in relapse risk for the smartphone intervention (hazard ratio [HR], 0.65; 95% CI, 0.39-1.09; log-rank P = .08). However, decreased relapse was observed for low-risk individuals (HR, 0.32; 95% CI, 0.12-0.88; log-rank P = .02) but not high-risk individuals (HR, 0.86; 95% CI, 0.47-1.57; log-rank P = .62). Reduced manic symptom severity was observed for low-risk individuals (mean [SE] difference, -1.4 [0.4]; P = .001) but not for high-risk individuals (mean [SE] difference, 0 [0.3]; P = .95). The smartphone-based self-management intervention decreased depressive symptom severity (mean [SE] difference, -0.80 [0.34]; P = .02) and improved relational quality of life (mean [SE] difference, 1.03 [0.45]; P = .02) but did not decrease percentage-time symptomatic (mean [SE] difference, -5.6 [4.3]; P = .20). CONCLUSIONS AND RELEVANCE: This randomized clinical trial of a smartphone-based self-management intervention did not detect a significant improvement in the primary outcome of time to relapse. However, a significant decrease in relapse risk was observed for individuals in asymptomatic recovery. In addition, the intervention decreased depressive symptom severity and improved relational quality of life. These findings warrant further work to optimize the smartphone intervention and confirm that the intervention decreases relapse risk for individuals in asymptomatic recovery. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03088462.
引用
- Goulding EH, Dopke CA, Rossom R, et al. Effects of a Smartphone-Based Self-management Intervention for Individuals With Bipolar Disorder on Relapse, Symptom Burden, and Quality of Life: A Randomized Clinical Trial. JAMA Psychiatry. 2023. PMID: 36542401. doi:10.1001/jamapsychiatry.2022.4304
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。